GlassScriptPhysician profile
Emily Jones
NPI 1326016445
$7,640.00
in general payments reported to CMS, 2019-2025
35 companies · $1,554 in 2025
The $1,554 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $216 · 2021: $927 · 2022: $1,234 · 2023: $1,541 · 2024: $1,675 · 2025: $1,554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,770.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,378.74 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,154.33 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $852.99 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $494.26 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $475.45 | 2021-2025 | |
| Pfizer INC. | $367.60 | 2019-2025 | |
| Astellas Pharma US INC | $310.02 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.70 | 2019-2025 | Jardiance, Tradjenta |
| Amgen INC. | $214.16 | 2020-2025 | Repatha, Otezla, Evenity |
| Amarin Pharma, INC. | $179.01 | 2019-2023 | |
| Exact Sciences Corporation | $166.39 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $161.55 | 2019-2023 | Belsomra, Steglujan, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.46 | 2019-2024 | Xifaxan, Trulance |
| Abbott Laboratories | $154.52 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| E.R. Squibb & Sons, L.L.C. | $141.56 | 2020-2025 | Eliquis |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.